Marfan Syndrome: Causes, Symptoms, and Treatment
This paper provides a comprehensive overview of Marfan syndrome, a relatively common autosomal dominant genetic disorder caused by mutations in the fibrillin-1 gene. Beginning with the disorder's historical discovery in 1896, the paper examines its epidemiology, wide-ranging clinical features—including cardiovascular defects, ectopia lentis, and skeletal abnormalities—and the molecular mechanisms behind it. It also addresses the considerable diagnostic challenges posed by variable symptom expression and phenotypic overlap with other syndromes, outlines current treatment strategies, and highlights notable individuals who have lived with or died from the condition. The paper concludes by emphasizing the urgent need for improved early screening and diagnostic tools.
- Historical Background: Discovery and early documentation of Marfan syndrome
- Epidemiology: Prevalence estimates and population distribution
- Clinical Features: Physical symptoms and diagnostic complexity
- Etiology: Fibrillin-1 mutations and TGFβ pathway disruption
- Diagnosis: Diagnostic methods, challenges, and genetic testing limits
- Treatment and Lifestyle Management: Medical interventions and activity recommendations
- Notable Individuals with Marfan Syndrome: Famous people affected by or lost to the syndrome
- Summary: Public health implications and call for better screening
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper moves logically from history through etiology to clinical management, giving readers a complete picture of the disorder without unnecessary repetition.
- Specific statistics (e.g., 75% of patients develop cardiac problems, 80% of adults show detectable lens dislocation) ground abstract medical claims in concrete, memorable figures.
- The inclusion of famous individuals adds accessibility and human interest without sacrificing scientific rigor.
Key academic technique demonstrated
The paper consistently distinguishes between what is known and what remains uncertain—for example, noting that the mechanism by which excess TGFβ causes Marfan symptoms "remains unknown," and that a definitive genetic test may not be available for some time. This epistemic honesty is a hallmark of strong medical writing and prevents overstating the evidence.
Structure breakdown
The paper is organized into eight clearly delineated sections. It opens with historical context, moves through epidemiology and clinical presentation, explains the underlying molecular biology, addresses diagnostic complexity, outlines treatment, highlights notable cases, and closes with a policy-oriented summary calling for better screening. Each section builds on the previous one, creating a coherent narrative arc from discovery to public health implication.
Historical Background
In 1896, the pediatrician Dr. Antoine Bernard-Jean Marfan described the exceptionally long, slender limbs and physique of a 5-year-old girl, Gabrielle P., before the Medical Society of the Hospital of Paris (Enersen). It is unknown whether Gabrielle P. actually suffered from what is now known as Marfan syndrome, but Dr. Henricus Jacobus Marie Weve was recognized as the first person to use the term "Marfan syndrome" to describe this common genetic disorder.
In the decades leading up to Dr. Weve's use of the term in 1931, other physicians had begun to document their encounters with this disease using radiological imaging (Enersen). Drs. Henri Mery and Leon Baonneix studied Gabrielle P. anew with this new technology in 1902 and noted a misaligned spine, thoracic asymmetry, long digits, cardiovascular abnormalities, and dislocation of the ocular lens. During the same year, Dr. Achard described a patient with similar characteristics, including joint hypermobility and a pattern of family inheritance.
Epidemiology
The estimated prevalence of Marfan syndrome can range between 1:3,000 (Lavall, Schafers, Bohm, and Laufs 228), 1:5,000 (NIAMS, "What is Marfan Syndrome?"), and 1:10,000 (Dean 724). The lowest estimate, by Lavall and colleagues, assumes that a significant number of people with Marfan syndrome remain undiagnosed (228). The prevalence of this disorder does not appear to be influenced by gender or ethnicity (NIAMS, "What is Marfan Syndrome?").
Works Cited
Beighton, Peter. Inherited Disorders of the Skeleton. New York, NY: Churchill Livingstone, 1978. Print.
Dean, John C.S. "Marfan Syndrome: Clinical Diagnosis and Management." European Journal of Human Genetics, 15.7 (2007): 724–733. Web. 5 Aug. 2012.
Enersen, Ole Daniel. Antoine Bernard-Jean Marfan. WhoNamedIt.com. n.p., 1994–2012. Web. 5 Aug. 2012.
England, Ellen. "What is Dural Ectasia?" MarfanLife.org. n.p., n.d. Web. 5 Aug. 2012.
Heart & Vascular Institute, Johns Hopkins University. "Marfan Syndrome: What is the Marfan Syndrome?" HopkinsMedicine.org. Johns Hopkins University, n.d. Web. 5 Aug. 2012.
Lavall, Daniel, Hans-Joachim Schafers, Michael Bohm, and Ulrich Laufs. "Aneurysms of the Ascending Aorta." Deutsches Ärzteblatt International 109.13 (2012): 227–233. Web. 5 Aug. 2012.
Massimini, Kathy, ed. Genetic Disorders Sourcebook. 2nd ed. Detroit, MI: Omnigraphics, 2000. Print.
NIAMS (National Institute of Arthritis and Musculoskeletal and Skin Diseases). Marfan Syndrome: Questions and Answers about Marfan Syndrome. National Institutes of Health, 2012. Web. 5 Aug. 2012.
NMF (National Marfan Foundation). "About Marfan Syndrome: Diagnosis." Marfan.org. National Marfan Foundation, 2012. Web. 5 Aug. 2012.
NMF (National Marfan Foundation). "About Marfan Syndrome: Notable Individuals & Celebrities with Marfan Syndrome." Marfan.org. National Marfan Foundation, 2012. Web. 5 Aug. 2012.
Thurmon, Theodore F. A Comprehensive Primer on Medical Genetics. New York, NY: Parthenon Publishing Group, 1999. Print.
Already a member? Log in
Unlock the rest of this paper
135,000+ research papers · AI writing tools · Plagiarism & AI detection
24-Hour Pass
Does not renew
Get 24-Hour PassMonthly
Renews at $12.99/month until canceled
Start MonthlyAnnual
Renews at $99/year until canceled
Start Annual- Unlimited AI writing tools
- Plagiarism and AI text detection tool
Plan details
Unlimited AI writing tools are for individual, non-automated use and are subject to our Terms of Service and abuse-prevention measures.
TextChecker scans: 1 during the 24-Hour Pass, or 5 per month with Monthly and Annual.
Prices exclude applicable tax.
Always verify citation format against your institution’s current style guide requirements.